Israel Englander Bei Gene, Ltd. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Millennium Management LLC holds 13,783 shares of BGNE stock, worth $2.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,783

Previous 4,720 192.01%

Holding current value

$2.79 Million

Previous $738,000 166.4%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$129.52 - $174.32 $1.17 Million - $1.58 Million	9,063 Added 192.01%	13,783 $1.97 Million
Q1 2024 May 15, 2024	SELL	$141.8 - $181.47 $369,247 - $472,547	-2,604 Reduced 35.55%	4,720 $738,000
Q4 2023 Feb 14, 2024	SELL	$158.67 - $201.58 $16.4 Million - $20.9 Million	-103,647 Reduced 93.4%	7,324 $1.32 Million
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $5.93 Million - $8.87 Million	33,253 Added 42.79%	110,971 $19.8 Million
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $9.95 Million - $12.7 Million	46,155 Added 146.23%	77,718 $16.8 Million
Q4 2022 Feb 14, 2023	SELL	$125.51 - $229.3 $2.11 Million - $3.86 Million	-16,825 Reduced 34.77%	31,563 $6.94 Million
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $1.6 Million - $2.46 Million	12,160 Added 33.57%	48,388 $6.52 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $4.09 Million - $7.3 Million	33,781 Added 1380.51%	36,228 $5.86 Million
Q4 2021 Feb 14, 2022	BUY	$248.56 - $389.34 $155,598 - $243,726	626 Added 34.38%	2,447 $663,000
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $603,782 - $975,195	-2,419 Reduced 57.05%	1,821 $661,000
Q2 2021 Aug 16, 2021	BUY	$292.75 - $367.01 $1.24 Million - $1.56 Million	4,240 New	4,240 $1.46 Million
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $6.25 Million - $9.17 Million	-23,997 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$221.31 - $316.61 $10.4 Million - $14.9 Million	-46,909 Reduced 66.16%	23,997 $6.2 Million
Q4 2019 Feb 14, 2020	BUY	$115.78 - $208.34 $4.11 Million - $7.4 Million	35,521 Added 100.38%	70,906 $11.8 Million
Q2 2019 Aug 14, 2019	BUY	$113.99 - $146.86 $1.76 Million - $2.26 Million	15,417 Added 77.21%	35,385 $4.39 Million
Q1 2019 May 14, 2019	BUY	$122.82 - $151.83 $1.63 Million - $2.02 Million	13,276 Added 198.39%	19,968 $2.64 Million
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $114,821 - $187,935	1,073 Added 19.1%	6,692 $939,000
Q3 2018 Nov 14, 2018	SELL	$152.62 - $189.66 $19.3 Million - $24 Million	-126,520 Reduced 95.75%	5,619 $968,000
Q2 2018 Aug 14, 2018	BUY	$152.5 - $216.77 $20.2 Million - $28.6 Million	132,139 New	132,139 $20.3 Million
Q4 2017 Feb 14, 2018	SELL	$79.6 - $114.73 $274,938 - $396,277	-3,454 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$66.19 - $103.46 $228,620 - $357,350	3,454	3,454 $357,000

Others Institutions Holding BGNE

# of Institutions

217

Shares Held

42.1M

Call Options Held

106K

Put Options Held

93.1K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $21B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account